Recent Updates
Recently added Catalysts

DCR-PDL1

Phase 1

Solid Tumors, Adult | Small molecule | Oncology |Novo Nordisk A/S|Trials Updated: Nov 6, 2025

DCR-PDL1 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Jul 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment32

FDA Designations

No designations recorded

DCR-PDL1 clinical trials

DCR-PDL1 · 1 trial · 1 indication

Phase 1 1
NCT06504368Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid TumorsSolid Tumors, Adult
RECRUITING32 Analytics
PHASE1RECRUITING
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Solid Tumors, Adult
NCT0650436832
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and Nature of Adverse Events (AEs)
Baseline to week 8
Incidence of Dose-limiting Toxicities (DLTs)
Baseline to week 8
Change From Baseline in Vital Signs: Oral, Tympanic, Temporal Artery Temperature
Baseline up to week 8

Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position.

Change From Baseline in Vital Signs: Systolic and Diastolic Blood Pressure
Baseline up to week 8

Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position.

Change From Baseline in Vital Signs: Pulse and Respiratory Rate
Baseline up to week 8

Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position. Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Change from Baseline in 12-lead Electrocardiogram (ECG): Heart Rate and Pulse Rate
Baseline to week 8
Change from Baseline in 12-lead Electrocardiogram (ECG): QRS intervals
Baseline to week 8

ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Change from Baseline in 12-lead Electrocardiogram (ECG): QT intervals
Baseline to week 8

ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Change from Baseline in 12-lead Electrocardiogram (ECG): QTcF intervals (QT Interval Corrected by the Fridericia Formula)
Baseline to week 8

ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Change from Baseline in Hematology Parameter: Red blood cells, White blood cells, Lymphocytes, Monocytes, Eosinophils, Neutrophils, Basophils and Platelets, Reticulocytes
Baseline to week 8
Change from Baseline in Hematology Parameter: Mean corpuscular volume (MCV)
Baseline to week 8
Change from Baseline in Hematology Parameter: Mean corpuscular hemoglobin (MCH)
Baseline to week 8
Change from Baseline in Hematology Parameter: Hemoglobin
Baseline to week 8
Change from Baseline in Hematology Parameter: Hematocrit and Mean corpuscular hemoglobin concentration (MCHC)
Baseline to week 8
Change from Baseline in Coagulation Parameter: International normalized ratio (INR)
Baseline to week 8
Change from Baseline in Coagulation Parameter: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT)
Baseline to week 8
Change from Baseline in Coagulation Parameter: Fibrinogen
Baseline to week 8
Change from Baseline in Clinical Chemistry Parameter: Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl transferase (GGT), Alkaline phosphatase (ALP), Lactate dehydrogenase (LDH) and Creatine kinase (CK)
Baseline to week 8
Change from Baseline in Clinical Chemistry Parameter: Total protein and Albumin
Baseline to week 8
Change from Baseline in Clinical Chemistry Parameter: Total bilirubin, Direct bilirubin, Fasting blood glucose, Creatinine and Blood urea nitrogen (BUN)
Baseline to week 8
Change from Baseline in Clinical Chemistry Parameter: Sodium, Chloride and Potassium
Baseline to week 8
Change from Baseline in Urinalysis Parameter: Glucose, Protein, Bilirubin and Urobilinogen
Baseline to week 8
Change from Baseline in Urinalysis Parameter: Specific Gravity
Baseline to week 8
Change from Baseline in Urinalysis Parameter: Potential of Hydrogen (pH) of Urine
Baseline to week 8
Change from Baseline in Urinalysis Parameter: Blood
Baseline to week 8
Change from Baseline in Urinalysis Parameter: Ketones and Nitrite
Baseline to week 8
Change from Baseline in Urinalysis Parameter: Leukocyte esterase
Baseline to week 8
Number of Participants with Change from Baseline in Physical Examination Findings: Cardiovascular, Respiratory, Gastrointestinal, and Neurological systems
Baseline to week 8

A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, and neurological systems.

Secondary Endpoints

Pharmacokinetic Plasma Concentrations of DCR-PDL1
Pre-dose up to 48 hours post-dose
Pharmacokinetic Urine Concentrations of DCR-PDL1
Up to 8 hours post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
DCR-PDL1EXPERIMENTALParticipants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.

Interventions

NameTypeDescription
DCR-PDL1DRUGSolution for IV Infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Male or female adults, aged greater than or equal to (≥) 18 years. * Participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-Hodgkin's lymphoma * that is refractory to standard therapy known to provide clinical benefit f...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about DCR-PDL1

What is DCR-PDL1?

DCR-PDL1 is an investigational small molecule oncology drug being developed by Novo Nordisk A/S for the treatment of adult solid tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA. It is being studied in a single active trial.

What is DCR-PDL1 used for in solid tumors?

DCR-PDL1 is being evaluated for the treatment of adult patients with solid tumors. It is an investigational therapy in Phase 1 testing, and its safety, tolerability, and pharmacokinetics are being assessed in a single clinical trial. It is not yet approved for any indication.

Who is developing DCR-PDL1?

DCR-PDL1 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. The company is the sponsor of the ongoing Phase 1 clinical trial for the drug in adult solid tumors.

What phase is DCR-PDL1 in?

DCR-PDL1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The only trial for DCR-PDL1 is currently recruiting participants.

What clinical trials is DCR-PDL1 in?

DCR-PDL1 is being studied in one clinical trial: NCT06504368, titled "Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors." The trial is a Phase 1, open-label, uncontrolled study recruiting 32 adults in the United States.

Explore more on BiopharmaWatch

Novo Nordisk A/S (NVO)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with DCompanies A to ZEvery biotech and pharma company we track